Terconazole
Terconazole is a triazole antifungal agent that inhibits lanosterol 14α-demethylase (CYP51), a cytochrome P450 enzyme essential for ergosterol biosynthesis in fungal cell membranes, leading to membrane disruption and fungal cell death. It is available as a topical vaginal cream and suppository for the treatment of vulvovaginal candidiasis, including non-albicans Candida species. Its triazole structure provides enhanced antifungal potency compared to imidazole antifungals in the treatment of vaginal infections.
Moleküler Ağırlık
532,5000 g/mol
LogP
4,80
TPSA
64,90 Ų
Lipinski RO5
Geçer
Etki Mekanizması
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
InChI
InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3
Molecular Formula
C26H31Cl2N5O3
HBD / HBA
- / 7
Döndürülebilir Bağlar
8
Ağır Atomlar
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Terconazole is a triazole antifungal agent that inhibits lanosterol 14α-demethylase (CYP51), a cytochrome P450 enzyme essential for ergosterol biosynthesis in fungal cell membranes, leading to membrane disruption and fungal cell death. It is available as a topical vaginal cream and suppository for the treatment of vulvovaginal candidiasis, including non-albicans Candida species. Its triazole structure provides enhanced antifungal potency compared to imidazole antifungals in the treatment of vaginal infections.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Terconazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1714574. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 441383. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="terconazole"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/terconazole/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/terconazole/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/terconazole/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="terconazole"></drugfyi-drug>